Cautious Progress for Semaglutide and Tirzepatide Amid Ocular Safety Concerns
PILLAR DIAGNOSTIC // WEEK 40
“Semaglutide and tirzepatide maintain a favorable efficacy profile in glycemic control, weight reduction, and cardiovascular/inflammatory risk mitigation, which aligns with patient need for cardioprotective therapies in an obese type 2 diabetes population at elevated cardiovascular risk. However, emerging safety signals—particularly ocular events and rare intestinal obstructions—combined with unresolved questions around lean mass changes and lacking mechanistic clarity, counsel caution. With initial Medicare negotiation pricing offering potential broader access, stakeholders must balance strong clinical benefits against undercharacterized risks.”
Proposed action
Adopt a cautiously optimistic stance: proceed with restricted implementation under enhanced pharmacovigilance. Prioritize post-market surveillance and targeted mechanistic studies to elucidate adverse event pathways (ocular and gastrointestinal) and lean mass effects. Reevaluate risk posture once new safety and mechanistic data become available.
THE MECHANICS
Spread & delivery
—
THE MACHINE
Evidence & systems
Semaglutide and tirzepatide markedly improve glycemic control, weight loss, cardiovascular and inflammatory risk profiles, and reduce stroke-related rebleeding and mortality, but they can cause variable lean mass changes and carry emerging visual safety signals.
THE MAP
Policy & population
Initial price offers for 15 drugs targeted by the Medicare Drug Price Negotiation Program in 2027 have been estimated, and obese type 2 diabetes patients face elevated risk of cardiovascular disease and major adverse events.
THE MOOD
Trust & behavior
Patients and clinicians express growing concern and caution over underrecognized and poorly characterized adverse effects of GLP-1 receptor agonists—including ocular events and rare intestinal obstructions—driving demand for cardioprotective or neutral medication options.